1. Introduction {#sec1}
===============

In recent decades, awareness of the importance of oral health in relation to well-being and general health has grown \[[@bib1]\]. Dental calculus, dental plaque, gingivitis, halitosis, and stain are all conditions of great concern in both objective and subjective perspectives. Gingivitis, inflammation of the gum, is one of the most common diseases in the world \[[@bib2]\]. Prevalence is high and varies extensively due to assessment method, population, and age group \[[@bib3], [@bib4]\]. The primary causative factor of gingivitis is dental plaque, a biofilm formed by bacteria that have been colonizing on the teeth for a prolonged period of time \[[@bib5], [@bib6]\]. Plaque-induced gingivitis can be prevented with good oral hygiene, which includes regular tooth brushing and interproximal cleaning \[[@bib7], [@bib8]\]. Moreover, patient-administered mechanical plaque control is an effective preventive measure.

Tooth stain may be due to several factors, for example, coffee, tea, tobacco, and wine. If dental plaque is not removed, it may lead to calculus formation, halitosis, and eventually periodontal disease \[[@bib9], [@bib10]\]. Dental calculus forms when non-mineralized biofilms rich in oral bacteria become mineralized with calcium phosphate mineral salts \[[@bib11], [@bib12]\]. This mineralized biofilm may develop both supra- and subgingivally. The significance of dental calculus in the initiation and progression of periodontitis has been demonstrated \[[@bib12]\]. Similar to gingivitis, bacterial plaque may also induce inflammation around dental implants, that is, peri-implant mucositis \[[@bib13]\], which can develop into peri-implantitis.

Halitosis (bad breath, malodor) has a mean prevalence of 31.8 % \[[@bib14]\] ranging from 1.5% to 100%, depending on how the condition has been assessed or defined \[[@bib15]\]. The degree of halitosis varies throughout the day, with higher levels often occurring in morning breath. The etiological factors are primarily related to the bacterial degradation of proteins, which creates high concentrations of volatile sulphur compounds \[[@bib16]\]. Halitosis may also originate from pathological conditions such as throat infections, tonsillitis, and lung disease \[[@bib16]\]. Today, subjective and objective methods are available for assessing VSCs in exhaled air. Halitosis treatment is focused on oral hygiene, in particular tooth brushing, as well as tongue cleaning. Mouth rinses and dentifrices containing various active ingredients, such as metal salts, essential oils, and chlorhexidine have also been found to be effective in reducing VSC levels \[[@bib17]\].

In home dental care, the most widely used method to clean teeth efficiently is tooth brushing with dentifrices \[[@bib18], [@bib19]\]. Today, numerous commercial dentifrices are available, and they are composed of different active ingredients, each with a special function, for example, anti-calculus agents, anti-bacterial agents, and anti-cavity agents. Fluorides have, in general, been considered the most important active ingredient in a toothpaste. Over the years, various fluoride formulations have been used, for example, sodium fluoride (NaF), sodium monofluorophosphate (SMFP), amine fluoride, and stannous fluoride (SnF~2~). The first toothpaste with a clinically proven anti-cavity effect contained SnF~2~ and was introduced in the 1950s \[[@bib20]\]. However, the SnF~2~ formula had some limitations, such as the potential to cause extrinsic tooth staining.

Aside from purported effects on gingivitis, caries, dental plaque, halitosis, and stain, dentifrices with an anti-calculus effect have been a focus of interest for many years. The first toothpaste to have a clinically proven anti-calculus effect was introduced in 1985 and contained sodium pyrophosphate as the anti-calculus ingredient \[[@bib21]\].

A longer chain variant of pyrophosphate, sodium hexametaphosphate (SHMP) with increased anti-staining and anti-calculus effects, was added to dentifrice formulations \[[@bib22], [@bib23]\]. This addition overcame the staining problem caused by SnF~2~.

Since SnF~2~ is still considered to be superior compared to other fluoride compounds, a literature review for evidence of its effect on various oral conditions is valuable. The aim of this review was to systematically examine the scientific evidence for the efficacy of stabilized SnF~2~ dentifrice in relation to dental calculus, dental plaque, gingivitis, halitosis, and stain.

2. Material and methods {#sec2}
=======================

2.1. Eligibility {#sec2.1}
----------------

A Population/Problems, Intervention, Comparison/Control, Outcome (PICO) process was used to develop the inclusion criteria: studies must be *in vivo* or *in situ*; the publication language, English; and publication year 1990 or later. Inclusion criteria concerning intervention, comparisons and outcome variables were specified for each category:

### 2.1.1. Population/problem {#sec2.1.1}

Individuals with, or at risk for, one or more of five dental problems: dental calculus, dental plaque, gingivitis, halitosis, and stain.

### 2.1.2. Intervention {#sec2.1.2}

Tooth cleaning with a manual or electric tooth brush and a stabilized SnF~2~ dentifrice, or with experimental slurries containing stabilized SnF~2~.

### 2.1.3. Comparison {#sec2.1.3}

Tooth brushing twice daily with another fluoridated or non-fluoridated dentifrice, a placebo, or no treatment.

### 2.1.4. Outcome {#sec2.1.4}

Dental calculus: the Volpe-Manhold Calculus Index \[[@bib24]\]; dental plaque: various plaque indices \[[@bib25], [@bib26], [@bib27]\]; gingivitis: the Gingival Index \[[@bib28], [@bib29]\], the Modified Gingival Index \[[@bib30]\], the Gingival Bleeding Index \[[@bib31]\], or the Bleeding Index \[[@bib32]\]; halitosis: a reduction in volatile sulphur compounds \[[@bib33]\]; and stain: the Lobene stain index \[[@bib34]\].

2.2. Exclusion criteria {#sec2.2}
-----------------------

Duplicates, reviews, *in vitro* studies, animal studies, and non-controlled studies were omitted. Other exclusion criteria were *(i)* the test dentifrice contained stannous chloride or SnF~2~ in combination with potassium nitrate or amino fluorides, *(ii)* the SnF~2~ formulation was applied in a gel, *(iii)* ionic or laser toothbrushes were used, *(iv)* a mouthwash was used ([Table 1](#tbl1){ref-type="table"}), *(v)* outcome data regarding dental plaque, gingivitis, stain, or halitosis were unclear.

2.3. Literature search strategy {#sec2.3}
-------------------------------

We searched Medline OVID (including Epub Ahead of Print, In-Process & Other Non-Indexed Citations), [Embase.com](http://Embase.com){#intref0010}, and the Cochrane Library using medical subject headings (MeSH) associated with SnF~2~, dentifrices, the dental problems being assessed in this review, and related dental problems. The MeSH terms identified in Medline were adapted to Embase and Cochrane. We also used free-text terms and, when appropriate, truncated and/or combined the search terms with proximity operators.

The following search terms were used: gingivitis, dental plaque, dental plaque index, plaque control, gingival hemorrhage, bleeding on probing, biofilms, inflammation, dental calculus, anti-calculus, calcificat, tartar, dental, tooth, teeth, tooth discolorations, stain, halitosis, malodor odor, breath, fetor oris, fetor ex, or foetor, periodontitis, aggressive periodontitis, chronic periodontitis, periodontal pocket, periapical abscess, periapical granuloma, peri-implantitis, tin fluorides, stannic, fluoride, difluoride, tetrafluoride, stannofluoride, snf, dentifrices, paste, and toothpaste; the free-text terms we used were crest pro health, crest gum care, and crest plus gum care.

Information specialists at the university library at Karolinska Institutet in Stockholm searched from database inception until January 2018 (dental calculus, dental plaque/gingivitis, stain, halitosis) according to the PRISMA flow chart (<http://prisma-statement.org/>). The authors also conducted searches by hand after reading the reference lists of retrieved full-text papers to identify additional articles.

2.4. Study selection {#sec2.4}
--------------------

The reviewers formed pairs. Each pair reviewed one of the problem categories: dental calculus, dental plaque, gingivitis, halitosis, and stain. Each of the reviewers in a pair independently screened all titles and abstracts for a category to identify potentially eligible studies. The reasons for excluding a study were noted ([Table 1](#tbl1){ref-type="table"}). Studies that met the inclusion criteria were obtained in full text and assessed for eligibility. When the two reviewers disagreed, consensus was reached by discussion. The reviewers were not blinded to authorship or journal. [Figure 1](#fig1){ref-type="fig"} summarizes the literature search and article selection in a flow chart.Table 1Inclusion and exclusion criteria.Table 1Inclusion criteriaRandomized controlled trials (RCTs)Controlled clinical trials (CCTs)In the control group: no limitationIn the test group: stannous fluoride (SnF~2~) or combinations:\
 0.454 % SnF2\
 0.454 % SnF2 + SHMP (sodium hexametaphosphate)\
 0.454 % SnF2 + 5% sodium polyphosphate\
 0.454 % SnF2 + calcium pyrophosphate\
 0.454 % SnF~2~ + 350 ppm NaF (sodium fluoride)Exclusion criteriaArticles published before 1990Only abstract/ErratumReviewsAnimal studiesIn vitro studiesNo control groupNo relevant outcome variableMouth rinse or gelIonized toothbrush or laser in the treatment with SnF~2~SnF~2~ + 5% KNO~3~ (potassium nitrate)SnF~2~ + AmF (amine fluoride)SnCl~2~ (stannous chloride)Figure 1Flow chart presenting the literature search for dental calculus, dental plaque/gingivitis, halitosis and stain. (n = dental calculus/dental plaque + gingivitis/halitosis/stain).Figure 1

2.5. Data extraction {#sec2.5}
--------------------

Data were extracted and tabularized from all studies meeting the inclusion and exclusion criteria ([Table 1](#tbl1){ref-type="table"}). The present review reports only baseline and final results. Mean values and standard deviations (SDs) or standard errors (SEs) were extracted from the studies.

2.6. Risk of bias assessment {#sec2.6}
----------------------------

Each reviewer in a pair independently scored the methodological quality of the included studies. Quality was rated using a risk bias assessment checklist developed by the Swedish Agency for Health Technology Assessment \[[@bib35]\]. The SBU risk bias checklist is similar to the Cochrane checklist (<http://www.cochrane.org/>). In short, selection bias, performance bias, detection bias, attrition bias, and reporting bias were rated. Based on this information, risk of bias was judged as low, medium, or high.

2.7. Data analysis {#sec2.7}
------------------

The outcome of the intervention compared to placebo was of interest for estimating treatment efficacy. Since few studies were available to form the same pairwise comparisons, a random-effect meta-analysis was applied only for 6-month gingivitis studies. All SE values were recalculated into SD using the formula $SD = SE \times \sqrt{N}.$ Since some studies used different indices to measure gingivitis the means and SDs of assessments of gingival inflammation reported at 6 months were used to estimate the standardized mean difference (SMD) and 95% confidence interval (95% CI).

Heterogeneity was quantified using I^2^ and tested using Cochran\'s Q statistic. A probability level of *P* \< 0.05 was considered significant.

3. Results {#sec3}
==========

The literature search identified 42 articles referring to dental calculus, 451 to dental plaque and gingivitis, 45 to halitosis, and 75 to stain ([Figure 1](#fig1){ref-type="fig"}). After duplicates were excluded, 279 abstracts remained and were screened. Two papers on dental calculus, 21 on dental plaque/gingivitis, 4 on halitosis, and 5 on stain were reviewed in full text. Hand searching yielded no additional articles.

3.1. Dental calculus {#sec3.1}
--------------------

The two included studies ([Table 2](#tbl2){ref-type="table"}) were published between 2005 and 2007. Both were double-blinded, randomized, and parallel-grouped 6-month trials representing 222 participants (age range 19--63 y) with 113 patients in test groups and 109 in control groups. The test toothpaste in both studies was 0.454% SnF~2~ + SHMP. One study used a positive control (0.243% NaF +0.3% triclosan; \[[@bib36]\], and one a negative (0.243% NaF; \[[@bib37]\]. After 6 months, the Volpe-Manhold Calculus Index showed 55%--56% lower values for the test toothpaste than either of the positive or negative controls. The differences were statistically significant.Table 2Characteristics of included studies on dental calculus.Table 2AuthorsStudy designStudy populationIntervention (I)Control (C )Treatment/OutcomeCommentsRisk(year)MethodsNumber (gender)ToothpastePositive/negativebrushingof biasDurationAge (range)CountrySchiff et alrandomizedn=80 (49 male/31 female)I: 0.454% SnF2 + SHMPC: 0.243% NaF + 0.3% TCNBrushing twiceBL:No drop outsHigh2005double-blind27.5 (19-45) yrs.positive controldaily for for 1 min.I: 16.66parallel groupC: 15.88Sponsored byI=40Procter & GambleV-MIC=406MUSAI: 5.41Superior anti-calculus6 MC: 15.79effect for SnF2% treatment diff.I vs C: 56% (p\<0.0001)Winston et alrandomizedn=142 (70 male/72 female)I: 0.454% SnF2 + SHMPC: 0.243% NaFBrushing twiceBL:Drop-out=4High2007double-blinddaily for for 1 min.I: 27.21parallel group34 (19-63) yrs.negative controlC: 27.84Sponsored byProcter & GambleV-MIUSA6M:I: 9.27Superior anti-calculus6 MC: 20.78effect for SnF2% treatment diff.I: vs C 55 (p\<0.001)[^1]

3.2. Dental plaque and gingivitis {#sec3.2}
---------------------------------

Twenty-one full-text articles published between 1995 and 2013 met the inclusion criteria ([Table 2](#tbl2){ref-type="table"}). [Table 3](#tbl3){ref-type="table"} presents the study design, characteristics, outcome variables, results, and risk of bias of the included studies in detail.Table 3Characteristics of included studies on dental plaque and gingivitis.Table 3AuthorsStudy designStudy populationIntervention (I)Control (C )Treatment/OutcomeOutcomeOutcomeCommentsRisk(year)MethodsNumber (gender)ToothpastePositive/negativebrushingPlaque IndexGingival IndexGingival Bleedingof biasDurationAge (range)CountryArchila et alrandomizedn= 186I: 0.454% SnF2 + SHMPC: 0.234% NaF + 0.3% TCNBaseline prophylaxis.GI: (mean ±SD)GB: (mean ±SD)Drop out: n=11Medium2004double-blindI: n= 95 (33 male/ 63 female)positive controlBrushing twiceBL:BL:parallel30.7±10.0 (17-65) yrs.daily for for 1 min.I: 0.51±0.32I: 40.0±25.7Sponsored bysingle centerSupervised twice-C: 0.50±0.25Cl: 39.8±20.3Procter & GambleC: n= 91 (30 male/ 61 female)daily 3 days/weekGI: (Löe & Silness 1963)29.4±9.1 (30 male/61 female)3M (mean ±SE)3 M (mean ±SE)GB: Gingival BleedingI: 0.18±0.01I: 13.9±1.05( no of sites)USAC: 0.31±0.01C: 24.6±1.076 M6M (mean ±SE)6M (mean ±SE)I: 0.27±0.02I: 21.0±1.46Cl: 0.37±0.02C: 28.9±1.49GI Reduction (%)GB reduction (%)3M: 42.6% p\< 0.0013M: 43.4% p=0.0016M: 25.8% p=0.0016M: 27.4% p=0.001Barnes et alrandomizedn=25I: 0.454% SnF2 +C: 0.234% NaF + 0.3% TCNBaseline prophylaxisMGMPI: (mean ±SD)No drop outsHigh2010double-blindR: 18-65 yrs.SHMP/ZN- lactatepositive controlScaling and prophylaxis,Study 1cross-overremove dental plaqueI: 22.05± 12.42Sponsored by3 studies -- conducted withand dental calculusC: 14.14± 8.02Procter & GambleModified Gingival Marginsame clinical procedures.before the studyPlaque index (MGMPI)Study 2USAWashout period --useI: 25.35± 10.4824 HColgate 0.76 % SMFPC: 12.95± 7.18Study 3I: 27.09± 11.95C: 9.65± 8.30% treatment diff.I vs. C: Advantage C.Study 1: 7.91 p=0.05Study 2: 12.4 p=0.05Study 3: 17.44 p=0.05Beiswanger et alrandomizedn= 463IA: 0.454% SnF2 +C: 0.243% NaFNo instructions.PLI: (mean ±SE)GI: (mean ±SE)GB: (mean ±SE) no of sitesDrop out: n=47Medium1995double-blindBL:2.08% sodium gluconateNegative controlBL:BL:BL:parallelIA: n=157 (50 male/107 female)IA: 1.03±0.03IA: 0.67±0.02IA: 17.6±1.2Sponsored bysingle center33.34 (18-68) yrs.IB: 0.454% SnF2 +IB: 0,97±0.04IB: 0,70±0.02IB: 18.2±1.3Procter & Gamble4.16% sodium gluconateC: 0.95±0.03IC: 0.70±0.02C: 18.7±1.1PLI: (Silness & Löe 1964)IB: n=153 (50 male/ 103 female)GI: (Löe 1967)34.13 (19-67) yrs.3M:3M:3M:GB: Gingival bleedingIA: 1.03±0.03IA: 0.68±0.02IA: 17.6±01.2(no of sites)C: n=153 (45 male/ 108 female)IB: 0.96±0.03IB: 0.70±0.02IB: 18.2±1.332.34 (18-64) yrs.C: 0.93±0.03C: 0.69±0.02C: 18.4±1.16 M6M:6M:6M:6M:IA: n=140 (44 male/ 96 female)IA: 1.03±0.03IA: 0.68±0.02IA: 17.6±1.233.79 (18-68) yrs.IB: 0.96±0.04IB: 0.69±0.02IB: 18.2±1.3C: 0.95±0.03C: 0.71±0.02C: 18.7±1.1IB: n=140 (49 male/ 91 female)34.55 (19-67) yrs.6M reduction6M reduction6M reductionIA and IB vs C:IA and IB vs C:IA and IB vs C:C: n=136 (41 male/ 95 female)IA: 2.6% NSIA: 18.8% NSIA: 30.5% NS32.64 (19-64) yrs.IB: 1.6% NSIB: 18.0% NSIB: 23.1% NSUSABeiswanger et alrandomizedN= 835I: 0.454% SnF2C1: 0.243% NaFOral prophylaxisPLI: (mean ±SE)GI: (mean ±SE)GB: (mean ±SE)Drop out: n=83Medium1997double-blindBL:Negative controlBL:BL:BL: (%)parallelI: n=278 (77 male/201 female)I: 0.73±0.02I: 0,86±0.02I: 24.876±1.05Sponsored bysingle center36.3 ±0.62C2) 0.243% NaF + PHENC1: 0.67±0.03C1: 0.84±0.02C1: 23.36±1.37Procter & Gamble(Listerine®)C2: 0.70±0.02C2: 0.88±0.02C2: 26.18±1.16PLI: (Silness & Löe 1964)C1: n= 144 (40 male/104 female)Positive controlC3: 0.74±0.03C3: 0.89±0.02C3: 24.87±1.8136.1 ± 0.90GI: (Löe 1967)3M:3M:3M: (%)C2: n= 289 (71 male/218 female)C3) 0.243% NaF + BakingI: 0.51±0.02I: 0.72±0.01I: 18.05±0.56GB: Gingival bleeding35.7 ±0.59soda + Hydrogen peroxideC1: 0.50±0.02C1: 0.79±0.01C1: 22.02±01.77(no of sites)Positive controlC2: 0.44±0.02C2: 0.73±0.01C2: 20.33±0.55C3: n=148 (40 male/108 female)C3: 0.54±0.02C3: 0.77±0.01C3: 21.31±0.766M36.5 ± 0.856M:6M:6M: (%)6MI: 0.55±0.02I: 0.64±0.01I: 16.13±0.65I: 267C1: 0.54±0.02C1: 0.78±0.02C1: 22.25±0.90CI: n=140C2: 0.48±0.02C2: 0.73±0.02C2: 20.95±0.63C2: n= 281C3: 0.58±0.02C3: 0.74±0.02C3: 21.82±1.1C3: n= 147No data regarding gender and6M PLI (%)6M GI (%)6M GB (%)mean ageI vs C3: 4.2I vs C1: 17.5 p=0.05I vs C1: 27.5 p=0.05C2 vs C3: 16.2 p=0.05I vs C2: 10.8 p=0.05I vs C2: 23.0 p=0.05USAC2 vs I: 12.5 p=0.05I vs C3: 13.8 p=0.05I vs C3: 26.1 p=0.05C2 vs C1: 10.8 p=0.05C2 vs C1: 7.4 p=0.05C2 vs C1: 5.9 NSC2 vs I: 2.0 NSC2 vs C3: 3.4 NSC2 vs C3: 4.0 NSC2 vs C4: 6.1 NSC3 vs C1: 4.2 NSC3 vs C1: 1.9 NSBellamy et alrandomizedn=21I: 0.454% SnF2 + SHMPC: 0.76% SMFP + 2%Brushing withDPIA: mean ±SE, % plaqueNo drop outsHigh2008double-blindZn-Citratstandardized fluoridecoveragecross-overR: 20-60 yrs.Positive control(non-antibacterial) TP forA.M. Pre-brushSponsored bytwo weeks.I: 9.63±106Procter & GambleDigital plaque imagingEnglandC: 12.90±1.01analysis (DPIA)A.M. Post-brush15 daysI: 4.89±0.36C: 5.76±0.34P.M.I: 9.15±1.12C: 11.92±1.06% treatment diff.A.M. Pre-brush 25.32 p=0.05A.M. Post-brush 15.13 NSP.M. 23.24 p=0.09Bellamy et alrandomizedn=25 (11 male/ 15 female)I: 0.454% SnF2 + SHMPC: 0.32% NaFPre-treatment with NaF TPDPIA: (mean ±SE) % plaqueNo drop outsHigh2009Adouble-blindNegative controlBrushing twice daily.Two treatment and a35.3 (25-57) yrs.No other oral hygiene aids.A.M. Pre-brushSponsored byfour-day washout period.I. 12.5±1.63Procter & GambleEnglandC. 16.24±1.63Digital plaque imaginganalysis (DPIA)A.M. Post-brushI. 5.39±0.8917 daysC. 6.52±0.89P.M.I. 9.46±1,26C. 12.22±1.26% treatment diff.A.M. Pre-brush 23.03p= 0.0001A.M. Post-brush 17.33p= 0.01P.M. 22.59 p= 0.0004Bellamy et alrandomizedn=27 (14 male/ 13 female)I: 0.454% SnF2 + SHMPC: 1400 ppm AlFDPIA: (mean ±SE) % plaqueDrop out: n=2High2009Bdouble-blind0.05% chlorhexidine +coverage:crossover35.2 (25-57) yrs.0.08% aluminium lactateA.M. Pre-brushSponsored byTwo treatment and a(AlF3/Chx)I: 13.08±1.46Procter & Gamblefour-day washout period.EnglandC: 16.16±1.46Positive controlDigital plaque imagingA.M. Post-brushanalysis (DPIA)I: 5.31±0.87C: 7.14±0.8717 daysP.M.I: 9.76±1.27C: 12.17±1.27% treatment diff.A.M. Pre-brush 19.37p=0.0043A.M. Post-brush 25.63p=0.0014P.M. 19.80 p=0.0057Boneta et alrandomizedn=109I: 0.454% SnF2 + SHMPC: 0.234% NaF + 0.3% TCNBrushing twice daily forPLI: (mean ±SD)GI: (mean ±SD)Drop out: n=12Medium2010double-blindPositive control1 min.BL:BL:parallelI: n=55 (14 male/41 female)I: 3.19±0.64I: 2.18±0.40Sponsored bysingle center39 (21-68) yrs.C: 3.16±0.64C: 2.17±0.36ColgatePLI= Turesky modification ofC: n= 54 (18 male/36 female)3M (mean ±SE)3M (mean ±SE)the Quigley and Hein40 (21-63) yrs.I: 2.46±0,51I: 1.48±0.25(Quigley & Hein 1962,C: 1.95±0.61C: 1.20±0.27Turesky et al 1970)USA6M (mean ±SE)6M (mean ±SE)GI: (Löe & Silness 1963)I: 2.36±0.55I: 1.40±0.28C: 1.75±0.65C: 1.16±0.296M6M Reduktion %6M Reduktion %I: 32.1I: 35.8C: 44.7C: 46.56M: % treatment diff.6M: % treatment diff.I vs C: 18.9 p=0.05I vs C: 17.1 p=0.05Gerlach & Aminirandomizedn= 97 (60% female)I: 0.454% SnF2C: 1000 ppm SMFP +MGI: (mean ±SD)GB: (mean ±SD)Drop out: n=3High2012controlled33.6 ±11.1 (18-66) yrs.450 ppm NaFBL:BL:clinical trialNegative controlI: 2.18 ± 0.10I: 14.9± 8.89Sponsored byI: n=49C: 2.19 ± 0.10C: 16.1± 9.72Procter & GambleMGI: Modified Gingivitis indexC: n=48(Lobene 1986)3M: no data in the article3M: (adjusted mean)USA1: 4.2GB: Gingival bleeding2: 15.4(no of sites)Improvement GBI %:3M1. -74% p=0.0012. 2% NSMallatt et alrandomizedn= 128I: 0.454 SnF2 + SHMPC: SMFPPLI: (mean ±SD)MGI: (mean ±SD)Drop out: n=12Medium2007double-blindNegative controlBL.BL.parallel, clinical studyAge: Range 18-65 yr.I: 2.88±0.34I: 2.00 ± 0.13Sponsored bysingle centerC: 2.79±0.42C: 2.00 ± 0.13Procter & GambleI: n=62 (25 male/ 37 female)PLI: Turesky Modified Quigley-6M:6M:Hein (Turesky et al 1970)C: n=66 (23 male/37 female)I: 2.20±0.40T: 1.58±0.31C: 2.34±0.49C: 1.90 ±0.21MGI: Modified gingival indexUSA(Lobene 1986)PLIMGI reduction %I vs C: 8.5 % p=0.001I vs C: 16.9 p=0.001GBI: Gingival bleeding index(Saxton & van der OuderaaGBI: mean ±SD1989)BL.I: 10.86±4.936MC: 10.90±3.926M:I: 5.08±4.89C: 8.53±4.48GBI reduction %I vs C: 40.8 p=0.001Mankodi et alrandomizedn= 130I: 0.454% SnF2 + SHMPC: 0.76% SMFPDental prophylaxisPLI: (mean ±SD)MGI: (mean ±SD)Drop out: n=13Medium2005double-blindNegative controlTooth brushing for 1 minBL:BL:parallelI: n=64 (20 male/44 female)2 times/dayI: 2.73±0.41I: 2.03±0.10Sponsored by37.1± 10.9 (18-65) yrs.C: 2.91±0.35C: 2.04±0.10Procter & GamblePLI: Turesky Modified Quigley-Hein (Turesky et al 1970)C: n=66 (23 male/43 female)3M (mean ±SE)3M (mean ±SE)38.5 ± 11.3 (18-64) yrs.I: 2.24±0.05I: 1.75±0.02MGI: Modified Gingival IndexC: 2.38±0.05C: 1.98±0.02(Lobene 1986)USA6M (mean ±SE)6M (mean ±SE)GBI: Gingival Bleeding IndexI: 2.14±0.05I: 1.57±0.03(Saxton & van der OuderaaC: 2.30±0.05C: 2.01±0.0319896M % treatment diff.6M % treatment diff.6MI vs C: 6.9 p=0.001I vs C: 21.7% p=0.001GBI: (mean ±SD)BLI: 9.39±3.22C: 8.67±3.403M (mean ±SE)I: 4.14±0.34C: 7.92±0.346M (mean ±SE)I: 3.81±0.40C: 8.88±0.396M % treatment diff.I vs C: 57.1% p=0.001Owens et alrandomizedn=138 (41 male/102 female)I: 0.454% SnF2C1: 0.1% NaF +Dental prophylaxis,PLI: (mean ±SD)GI: (mean ±SD)Drop out: n=5Low1997single-blind0.76% SMFPremove plaque andBL.BL.parallel, comparisonAge: 18-65 yr.Negative controlcalculusI: 2.04±0.18I: 1.45±0.28No informationBrush 2 times a day forC1: 2.04 ±0.24C1: 1.38±0.20regarding sponsorPLI= Turesky modification ofI:n= 34C2: 0.8% NaF + 0.3% TCN18 weeks.C2: 2.12±0.21C2: 1.42±0.25the Quigley and HeinC1:n= 330.75% zn-citrateC3: 2.13±0.25C3: 1.41±0.21(Quigley & Hein 1962,C2:n= 35Positive controlTuresky et al 1970)C3:n= 3618W18WC3: 0.32% NaF + 0.3% TCNI: 1.91±0.03I: 1.21±0.02GI: Gingival indexEnglandPositive controlC1: 1.88±0.03C1: 1.22±0.02(Mandel-Chilton 1977C2: 1.86±0.03C2: 1.21±0.02modification of the Loe &C3: 1.83±0.03C3: 1.24±0.02Silness (1963)% treatment diff.% treatment diff.4 GroupsI: 6.4I: 16.6C1:7.8C1: 11.618 WC2: 12.3C2: 14.8C3: 14.1C3: 12.1NSNSPapas et alrandomizedN= 334I: 0.454 SnF2C: 0.234% NaF + 0.3% TCNNo treatmentBOP (mean ±SD)Drop out: n=106Medium2007double-blindPositive controlBL:parallelI: n=163 (77 male/86 female)I: 94.6±19.5Sponsored by626.2 ±9.36 (40-79) yrs.C: 88.3±27.9Procter & GambleBleeding on probing (BOP)1 Yrs.:2 Yrs.C: n=171 (76 male/95 female)I: 7.4±20.866.3±9.31 SD (41-80) yrs.C: 9.6±23.2USA2 Yrs.:I: 33.5±35.2C: 32.5±32.72 Yrs.I vs C: 61.1% vs 55.8% NSPerlich et alrandomizedn= 328I: 0.454% SnF2C: 0.243% NaFA 3-month pre-test periodPLI: (mean ±SE)GI: (mean ±SE)GB: (mean ±SE)Drop out: n=55High1995double-blindNegative controlwhere all subjects brushedBL:BL:BLparallelI: n=154 (51 male/ 103 female)with 0.243% SodiumI: 1.94±0.04I: 0.68±0.02I: 14.43±0.94Sponsored by37.3 (19-69) yrs.fluoride TP.C: 1.90±0.04C: 0.68±0.02C: 16.40±1.03Procter & GamblePLI= Turesky modification ofthe Quigley and Hein3M3M3MIdentical data as(Quigley & Hein 1962,Cl: n=174 (60 male/ 114 female)I: 1.99 ±0.12I: 2 0.43±0.01I: 7.23±0.32presented inTuresky et al 1970)36.5 yr. (19-48) yrs.C: 2.07±0.12C: 0.53±0.01C: 10.52±0.47McClanahan et al1997, butGI: (Löe & Siless 1967)USA6M6M6Mexkluding TCN.I: 2.16±0.13I: 0.41±0.01I: 5.71±0.39GB: Gingival BleedingC: 2.23±0.13C: 0.52±0.01C: 8.57±0.43(no of sites)PLI (Increase)GINo of GBI sites:I: -0.23 (11.9%)I: 0.27 (39.7%)I: 8.7% (60.4)C: -0.43 (-22.6%)C: 0.18 (25%)C: 7.8% (47.7%)6M - NS6M p=0.056M p=0.05Sharma et alrandomizedn= 114 subjectsI : 0.454% SnF2C: 0.234% NaF + 0.3% TCNDental prophylaxis, brushRMNPI: (mean ±SD)Drop out: n=8High2013double-blindPositive controlfor at least 1 min 23WparallelI: n= 56 (21 male/39 female)times/dayI: 0.39 ±0.01Sponsored by36.4 ±11.8 (21-71) yrs.C:0.56±0.01Procter & GambleRMNPI: Modification of theNavy Plaque indexC: n= 58 (21 male/39 female)6W(Rustogi et al. 1992)38.6 ±13.7 (20-82) yrs.I: 0.27±0.01C:0.50±0.016WUSA% treatment diff.I vs C:3W: 29.7% p=0.00016W: 44.9% p=0.0001Shearer et alrandomizedn= 110 (male)I: 0.454% SnF2C1: 0.243% NaF + TCNScaling and rotplaningPLI: (mean ±SD)MGI: (mean ±SD)Drop out: n=11High2005double-blind25-50 yrs.+ Zn-citrateand oral hygiene3W3W3-arm parallelPositive controlinstructionI: 1.04±0.03I: 0.91 ±0.07No baseline dataI: n= 39C1: 1.08±0.03C1: 1.07 ±0.09PLI: (Löe 1967)C1: n= 36C2: 0.243% NaFC2: 1.13±0.03C2: 1.43 ±0.07No sponserC2: n = 35Negative controlMGI: Modified Gingival IndexI vs CI: NSI vs C2: p=0.0003(Lobene 1986)USAI vs C2: NSI vs CI: NSC1 vs C2: NSC1 vs C2: p=0.01GBI: Gingival Bleeding Index(Saxton 1989)GBI (mean SD)3W21 DaysI: 0.33 ±0.03C1: 0.3 ±0.03C2: 0.51 ±0.03I vs C2: p=0.0003I vs C1: NSC1 vs C2: p=0.0003White et al.randomizedn= 16 (6 male/10 female)I: 0.454% SnF2 + SHMPC: 0.243% NaFTreatment period (TP) 1:DPIA: Plaque % mean ±SDNo drop outsHigh2006blindedNegative controlIncluding toothbrushing3-arm cross-over study33.2. (24-38) yrs.with NaF TPTP1: Plaque coverage:Sponsored by3-treatment period within theProcter & Gamblesame groupUSATP 2:Pre-brushing: 13.3% ±4.27Modified hygiene regimenPost-brushing: 6.4% ±1.80Digital plaque imagingwas applied using NaF TPanalysis (DPIA).including a period of 24 HTP2:of non-brushingPre-brushing: 18.4 ±5.972WPost-brushing: 7.3 ±3.64TP 3:24 H non-brushingTP3:regimen was continuedPre-brushing: 15.2 ± 6.87using SnF2 + SHMP TPPost-brushing: 6.8 ±3.52Reduction %:TP3 vs TP1, TP2: 17%Advantage TP3.White 2007double-blindn= 14I: 0.454% SnF2C.: 0.243% NaFDental prophylaxisDPIA: Morning Pre-BruchNo drop outsHighcross-overNegative controlperformed by subjectsRegrowth % ±SD33 yrs.I: 10.4 ±4.4Sponsored byDigital plaque imagingCl: 13.8 ± 5.5Procter & Gambleanalysis (DPIA)USAMorning Post-BrushingI: 6.2 ± 2.6C: 6.3 ±3.3Afternoon RegrowthI: 8.1± 3.9C: 11.2 ±5.1% treatment diff.Morning Pre-BrushI vs C: 24.4 p=0.0002Moring Post-BrushI vs C 1.7 NSAfternoon RegrowthI vs C: 27.9 p=0.0003Willumsen et aldouble-blindn= 40I: 0.4% SnF2C: 0.2% NaFBefore the two periods,PLI: (mean ±SD)GI: (mean ±SD)Excluded =4Medium2007cross-overNegative controlthe subjects had theirBL: (all surfaces)BL: (all surfaces)Drop-out= 488.7 (82-98)teeth professionallyI and C: 1.44 ± 0.48I and C: 1.29 ± 0.38PLI: (Silness & Löe 1964)cleaned.No sponsorNorway4W:4W:GI: (Löe & Silness 1963)I: 1.14± 0.40I:1.22± 0.30C: 1.28± 0.34Ctrl: 1.22± 0.274 W% treatment diff.% treatment diff.I: 20.8 vs. C: 11.1I: 7.0 vs. C: 7.0p=0.001NSYates et alrandomizedn= 69 /21 daysI: 0.454% SnF2C: 0.24% NaFProfessional prophylaxis,PLI: (mean ±SE)MGI: (mean ±SE)GB: (mean ±SE)Drop-out: n=6Low2003double-blindn= 67 /42 daysNegative controlallocated toothpaste andFor unshielded teethFor unshielded teeth (thatFor unshielded teeth (that(42 days)parallela standard toothbrush(that have been shielded)have been shielded)have been shielded)no data whichI: n=36 (7 male/ 29 female)Oral hygiene InstructionsBL: 0I: BL: 1.54±0.07I: BL: 0.33±0.04group21 days experimental gingivitis33.1 (20-60) yrs.21 days:1.50±0.08I: 21 days:1.74±0.05I: 21 days: 0.62± 0.03protocol and a 6 week (42 days)42 days: 1.07± 0.08I: 42 days: 1.17± 0.08I: 42 days: 0.43± 0.03No sponsorhome-use protocolC: n=35 (7 male/ 28 female)33.6 (21-63) yrs.C: BL: 0C: BL: 1.62±0.06C: BL: 0.41±0.04PLI: (Löe 1967)21 days:1.73±0.06C: 21 days:1.85±0.05C: 21 days: 0.67± 0.04United Kingdom42 days: 1.05± 0.09C: 42 days: 1.25± 0.07C: 42 days: 0.49± 0.04MGI: Modified gingival index(Lobene et al. 1986)Reduction: day 21 to day 42.MGI reduction 21 -- 42 dayGB reduction: 21 to 42days.I: 0.43 vs C: 0.68I: 0.57 vs C: 0.60I: 0.19 vs C: 0.18GB= Gingival bleedingI vs C: NSI vs C: NSI vs C: NSTeeth covered by tooth shieldFor unshielded teethFor unshielded teethFor unshielded teeth21 Days /42 Days(mean ±SE)(mean ±SE)(mean ±SE)I: BL: 0I: BL: 1.43± 0.07I: BL: 0.29± 0.0321 days:0.78± 0.06I: 21 days: 1.27± 0.07I: 21 days: 0.34± 0.0342 days: 0.81± 0.07I: 42 days: 0.95± 0.08I: 42 days: 0.37± 0.02C: BL: 0C: BL: 1.43± 0.07C: BL: 0.34± 0.0321 days:0.76± 0.07C: 21 days: 1.25± 0.06C: 21 days: 0.33± 0.0342 days: 0.77 ± 0.07C: 42 days: 1.02± 0.07C: 42 days: 0.38± 0.03PLI reduction: B to 42 days.MGI reduction: B to 42 days.GB reduction: B to 42 days.I: -0.81 vs C: -0.77I: 0.48 vs C: 0.41I: -0.08 vs C: - 0.0I vs C: NSI vs C: NSI vs C: NS[^2]

The studies included various study population such as patients, students, volunteers or subjects employed at dental product companies. The number of subjects varied greatly, ranging from 14 to 835 subjects. The 21 included studies comprised 3221 subjects. The duration of the studies ranged from 24 h to 2 years. One study had a duration of 2 years \[[@bib38]\], 8 studies of 6 months \[[@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46]\], one study of 4.5 months \[[@bib47]\], five studies of 3--12 weeks \[[@bib48], [@bib49], [@bib50], [@bib51], [@bib52]\], four studies of 14--17 days \[[@bib53], [@bib54], [@bib55], [@bib56]\], and two studies of 24 h \[[@bib57], [@bib58]\]. Most test products contained 0.454% SnF~2~ + SHMP as the active ingredients. One study, however, contained sodium gluconate and two contained zinc citrate. The control dentifrices in 12 studies contained between 0.1% and 0.15% fluoride as sodium fluoride. Eight trials also included 0.3% Triclosan (TCN) one trial included phenolics (Listerine) and Baking soda + Hydrogen peroxide and one trial included Chlorhexidine as a positive control.

Various indices were used to assess the presence and/or amount of plaque at the examinations. Two studies measured the percentage of surfaces harboring plaque in relation to the total number of tooth surfaces. Four studies \[[@bib40], [@bib41], [@bib51], [@bib52]\], assessed plaque according to the plaque index \[[@bib26]\]; these studies reported a mean percentage reduction of 6.2% (range 1.6%--12%) for the SnF~2~ dentifrice compared to a negative control. Six studies \[[@bib42], [@bib43], [@bib44], [@bib45], [@bib46]\]; used the modified Quigley and Hein Index \[[@bib25], [@bib27]\] and reported a mean reduction in plaque of 15.3% (range 3.9%--25.8%) for the SnF~2~ dentifrice compared to a negative control.

Gingival inflammation was assessed in 15 of the 21 studies ([Table 2](#tbl2){ref-type="table"}). Some used more than one index to measure the level of gingival inflammation. The mean reduction in gingival inflammation, registered as mean GI change, was 17.2% (range 5.3%--25.8%) greater in the SnF~2~ groups than in the sodium fluoride groups The reduction in percentages of sites showing gingival bleeding was 32.4% greater in the SnF~2~ groups (range 11.6%--72%).

[Figure 2](#fig2){ref-type="fig"} shows the results of the meta-analysis of gingival inflammation and the 6-month studies \[[@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib46]\]. Brushing with SnF~2~ toothpaste yielded significantly higher reductions in gingival inflammation. The SMD was -0.63 (95% CI: -1.11 to -0.15) with a significant reduction in the SnF~2~ group (*P* = 0.010) compared with the controls. When compared with negative controls only, the anti-gingivitis effect of SnF~2~ had a significant SMD of -0.93 (95% CI: -1.40 to -0.46; *P* = 0.0001) (see [Figure 3](#fig3){ref-type="fig"}).Figure 2Forrest plot of baseline and after 6 month values (Standardized mean difference: SMD) of the gingivitis indices for the studies using a stannous fluoride (SnF~2~) dentifrice compared to control dentifrice (positive and negative controls).Figure 2Figure 3Forrest plot of baseline and after 6 month values (Standardized mean difference: SMD) of the gingivitis indices for the studies using a stannous fluoride (SnF~2~) dentifrice compared to control dentifrice (negative control, NaF).Figure 3

3.3. Halitosis {#sec3.3}
--------------

[Table 4](#tbl4){ref-type="table"} lists the four included studies on halitosis, which were published between 1998 and 2010. The studies were randomized and had a cross-over \[[@bib59], [@bib60], [@bib61]\] or parallel design \[[@bib33]\]. They evaluated the effect of either one-time \[[@bib59]\] or repeated brushing \[[@bib33], [@bib60], [@bib61]\]. The intervention was brushing with a toothpaste containing 0.454% SnF~2~ alone \[[@bib33], [@bib59], [@bib60]\], in combination with sodium fluoride \[[@bib61]\], or in combination with tongue brushing \[[@bib60]\]. Both single use and repeated exposure reduced breath malodor when using a SnF~2~ toothpaste in comparison to control products. The studies reported a significant reduction in VSC after single use \[[@bib33], [@bib61]\] as well as after cumulative use and overnight readings \[[@bib33], [@bib59], [@bib60], [@bib61]\].Table 4Characteristics of included studies on halitosis.Table 4AuthorsStudy designStudy populationIntervention (I)Control (C )Treatment/OutcomeCommentsRisk(year)MethodsNumber (gender)ToothpastePositive/negativebrushingof biasDurationAge (range)CountryChen et alrandomizedn=33 (14male/19 female)I1: 0.454% SnF2C1: 0.243% NaFBrushing three24 HNo drop outHigh2010examiner-blind25 yrs.negative controltimes during 24 HI1: 93.69crossoverI2: 0.454% SnF2 +I2: 91.84Sponsored byUSAtongue brushingC2: 0.243% NaF +Procter & GambleBreath measurementtongue brushingC1: 113.30at 24 and 28 HPositive controlC2: 105.64Halimeter (hydrogenI1 + I2: 92.8sulfide, methylC1 + C2: 109.9mercaptanppb)\"28 HI1: 52.98I2: 54.60C1: 66.69C2: 68.72I1 + I2: 53C1 + C2: 66.7Farrell et alTwo RCTsHealthy adults withI: 0.454% SnF2C: 0.243% NaFSingle day productStudy I (mean ± SD)No drop outHigh2007cross-over double-blindhistory of halitosisnegative controluse (2 brushings)I: 4.59 ± 0.14Breath measurementC: 4.81 ± 0.14Sponsored byat 24 HProcter & GambleStudy 1Study II (mean ± SD)Study 1n=26 (13 male/13 female)I: 5.72 ± 0.09Halimeter (hydrogen38.4 ± 6.7 yrs.C: 5.94 ± 0.09sulfide, methylmercaptanppb)\"Study IIn=49 (14 male/35 female)Study II44.2 ± 12.7 yrs.Hedonic (9-point scale)5 WUSAFeng et alRandomizedn=100 (32 male/68 female)I: 0.454% SnF2 + NaFC I: 0.243% NaF (USA)Partly supervised3 HNo drop outHigh2010controlled34 (19-62) yrs.negative controlbrushing up to threeI: 88.3single-blindtimesC: 95.7Sponsored bycrossoverUSA (Study I)C2: 0.321% NaF (China)Procter & GambleChina (Study II-IV)negative control24 HData presented asI: 140.7results from meta-C: 157.3analysis of fourclinical trials.27-28 HI: 75.2Halimeter VSCC: 99.6Readings after 3-4 H,24 H and 27-28 HGerlach et alRandomizedn=384I: 0.454% SnF2CI: 0.243% NaF +5%Partly supervisedOrganoleptic score2% drop outHigh1998controlled(79% female/21% male)pyrophosphateon examination days3/6/8 Hparallell grouppositive controlI: 2.85/3.40/3.99Sponsored by44.5 (18-77) yrs.CI: 3.09/3.45/4.04Procter & GambleFluoride groupsC2:0.24 NaF +C2: 3.30/3.57/4.01Five-day periodUSA0.30% TCNC3: 3.23/3.42/4.01positive controlOrganoleptic scoring99/102/104 HHalimeter VSC (ppb)C3: bottled distilledI: 2.90/3.19/3.73waterCI: 3.33/3.57/4.10Readings after 3, 6negative controlC2: 3.43/3.64/4.18and 8 H (single use)C3: 3.54/3.73/4.13and 99, 102 and 104H (cumulative use)ppb3/6/8 HI: 4.39/3.97/4.09CI: 4.51/3.99/4.19C2: 4.50/4.02/4.18C3: 4.56/4.04/4.2099/102/104 HI: 4.07/3.83/4.00CI: 4.29/4.03/4.16C2: 4.34/4.03/4.29C3: 4.48/4.11/4.29[^3]

3.4. Stain {#sec3.4}
----------

[Table 5](#tbl5){ref-type="table"} presents the five included studies on stain, which were published between 2005 and 2013 \[[@bib36],[@bib62], [@bib63], [@bib64], [@bib65]\]. The test period varied between 2 and 6 weeks. All studies were controlled, randomized, double-blinded, and parallel-grouped, and represented 488 patients (aged 19--74 yr) with 240 patients in the test groups and 248 in the control groups. In four studies, the test toothpastes contained 0.454% SnF~2~ + SHMP \[[@bib36], [@bib62], [@bib63], [@bib65]\] and were compared with a positive control of 0.243% NaF +0.3% triclosan toothpaste. The fifth study \[[@bib63]\] examined a stannous chloride and sodium fluoride toothpaste but had a positive control with only 0.454% SnF~2~. The overall results showed that the 0.454% SnF~2~ + SHMP toothpastes and the triclosan controls reduced the Lobene stain index, but at the end of the test periods, no significant differences in stain reducing effect were found. While there were no significant differences in mean Lobene scores between the stannous chloride and the triclosan dentifrices, the toothpaste with only SnF~2~ had a higher stain score after 5 weeks than at baseline \[[@bib63]\].Table 5Characteristics of included studies on stain.Table 5AuthorsStudy designStudy populationIntervention (I)Control (C )Treatment/OutcomeCommentsRisk(year)MethodsNumber (gender)ToothpastePositive/negativebrushingof biasDurationAge (range)CountryHe et alrandomizedStudy 1:I: 0.454% SnF2 + SHMPC: 0.243% NaF + 0.3% TCNBrushing twiceStudy I:Study I:High2007double-blindn=56 (26 male/26 female)positive controldaily for for 1 min.BL: I: 2.64, C: 2.45Droup-outs= 4parallel group6 W: I: 1.05, C: 0.81Study 2:% treatment diff.Study II:Lobene stain indexn=58 (19 male/39 female)I vs C= nsDroup-outs= 26 W30-70 yrs.Study II:Sponsored byBL: I: 3.36, C: 3.17Procter & GambleUSA6W: I: 0.31, C: 0.15% treatment diff.Equal effect betweenI vs C= nstest and controlHe et alrandomizedn=98 (32 male/66 female)I: 0.454% SnF2C1: 1450 ppm NaF+ SnClBrushing twiceBL: I: 0.42Drop-out=2High2010double-blind19-63 yrs.positive controldaily for for 1 min.C1: 0.52, C2: 0.47,parallel groupC3: 0.40Sponsored byI: n= 14C2: 1450 ppm NaF+ SnClProcter & GambleLobene stain indexC1: n= 28positive control5W: I: 0.801968C2: n= 28C1: 0.37, C2: 0.40The I TP was lessC3: n= 28C3: 1450 ppm NaF+0.3% TCNC3: 0.30effect5 Wnegative controlUSA% treatment diff.C1 vs C2 vs C3 = nsI vs other 3 groups:p\<0.0001Nehme et alrandomizedn= 137I1: 0.454% SnF2 + SHMPC= 0.76% MFPBrushing twiceBL: I1=0.36, I2= 0.32Drop-out=6High2013double-blindnegative cocntroldaily for for 1 min.C=0.30parallel groupI1:= 21I2: 0.454% SnF2 + STPSponsored byI2:= 578W: I1=0.35, I2= 0.28GlaxoSmithKlineLobene stain indexC: n= 59C=0.281968Equal effect betweenUSANo diff. I vs Ctest and control8 WSchiff et alrandomizedn= 80 (49 male/31 female)I: 0.454% SnF2 + SHMPC: 0.243% NaF + 0.3% TCNBrushing twiceBL: I=0.0, C=0.0No drop-outHigh2005double-blind27.5 (19-45) yrs.positive controldaily for for 1 min.parallel group6M: I=0.02, C=0.0Sponsored byI= 40No diff. BL vs 6MProcter & GambleLobene stain indexC= 401968Equal effect betweenUSAtest and control6 MTerézhalmy et alrandomizedStudy 1:Study I:Study I:Brushing twiceStudy 1:No drop-outHigh2007double-blindn=29 (12 male/17 female)I: 0.454% SnF2 + SHMPC: 0.243% NaF + 0.3% TCNdaily for for 1 min.BL: I=1.06, C=1.05parallel group50.4 (21-62) yrs.positive control2W: I=0.57, C=0.53Sponsored byStudy III vs C: nsProcter & GambleLobene stain indexStudy 2:I: 0.454% SnF2 + SHMPStudy II:1968n=30 (17 male/13 female)C: 0.243% NaF + 0.3% TCNStudy 2:Equal effect between47.6 (33-59) yrs.positive conrolBL: I=1.68, C=1.48test and control2 W2W: I=1.41, C=1.40USAI vs C: ns[^4]

4. Discussion {#sec4}
=============

In the present review, toothpastes containing SnF~2~ have been proven to have preventive and therapeutic effects against dental calculus, dental plaque, gingivitis, halitosis and stain. Comparisons with the effects of other toothpastes on these conditions favored a toothpaste containing SnF~2~. However, the meta-analyses on gingivitis showed a substantial heterogeneity in the results of the individual randomized trials.

4.1. Dental calculus {#sec4.1}
--------------------

The significant reduction in calculus formation that occurred after 6 months of testing a toothpaste containing SnF~2~ and a calcium phosphate-mineralization inhibitor (SHMP) compared with other toothpastes indicated a beneficial effect. Due to their hardness, calculus deposits can only be removed by scaling and polishing the teeth. SHMP acts by reducing the rate and extent of mineralization, thereby reducing calculus build-up. In the Winston et al. \[[@bib37]\] study, home-based and unsupervised use of a SnF~2~ dentifrice during normal hygiene procedures effectively inhibited calculus regardless of the baseline levels of calculus. The significant anti-calculus efficacy that was observed is further evidence of the capacity of SHMP to interfere with calculus formation.

4.2. Dental plaque and gingivitis {#sec4.2}
---------------------------------

A recent systematic review reported that use of a dentifrice with tooth brushing had a weak additional inhibitory effect on plaque regrowth when compared with tooth brushing alone \[[@bib66]\]. The present systematic review demonstrated an increased plaque-reducing effect of a toothpaste containing SnF~2~ compared with other toothpastes. Depending on the plaque index used and study duration, the reduction in dental plaque ranged from 1.6% to 25.8%. The effect was observed in both 24-hour as well as 6-month studies, indicating that both short- and long-term use of a SnF~2~ dentifrice has a plaque inhibitory effect. Although long-term studies are desirable, studies of more than 6 months require a degree of compliance among participants that is sometimes difficult.

The present review found evidence for both direct and indirect effects on gingivitis development of brushing with a SnF~2~ dentifrice. The indirect effect refers to the amelioration of gingivitis due to plaque reduction; the direct effect refers to a possible anti-inflammatory action, which both triclosan and SnF~2~ have demonstrated, independent of how they affect bacteria \[[@bib67]\]. The meta-analysis of the 6-month studies showed that stabilized SnF~2~ significantly reduced gingival inflammation compared to positive and negative control dentifrices. The results of the present review are in line with the Paraskevas et al. \[[@bib68]\] study, which reported that dentifrice containing SnF~2~ reduced dental plaque as well as gingivitis.

4.3. Halitosis {#sec4.3}
--------------

The four papers \[[@bib33], [@bib59], [@bib60], [@bib61]\] evaluating the effect of a SnF~2~ toothpaste on halitosis vary in number of exposures and in time point for measurement after exposure to the toothpaste. The overall picture, however, is that SnF~2~ reduces the level of halitosis to a larger extent than comparative toothpaste products. The data are based on the combined level of hydrogen sulfide and methyl mercaptan, representing the VSCs produced by gram negative anaerobes most commonly found in bad breath. Other compounds, such as dimethyl sulfide and fatty acids, may also contribute \[[@bib17]\]. The four papers reported limited information on the volunteers, but subjects with medical and oral conditions that could interfere with study measurements seem to have been excluded. The exact mechanism behind the positive findings is not fully known, but the antimicrobial effect of the SnF~2~ compound is believed to play a significant role and also the effect of zinc in those toothpastes containing zinc citrate.

4.4. Stain {#sec4.4}
----------

Several toothpastes on the market claim better stain-reducing capacities compared to conventional toothpastes. Historically, this effect has been due to the abrasive ingredient in the toothpastes. The studies in the present review have shown that a SnF~2~ + SHMP toothpaste plays an important role in stain reduction. All studies demonstrated that the SnF~2~ + SHMP toothpaste exhibited a stain-reducing effect equal to that of various control toothpastes. Clinical studies have shown that use of the polypyrophosphate formulation SHMP as the sole active ingredient in a toothpaste reduces the development of stain \[[@bib69]\]. SHMP has the capacity to interact with stained pellicle films, remove the stain material, and then prevent adsorption of new chromogens by leaving a protective coating on the tooth surface \[[@bib69]\].

4.5. Clinical relevance {#sec4.5}
-----------------------

Several aspects affect the clinical significance of the findings of the present review. For example, other ingredients in a toothpaste may contribute to the effects of a toothpaste on dental plaque, gingivitis, stains, and to some extent halitosis. An abrasive ingredient is necessary to remove plaque and biofilm \[[@bib70], [@bib71]\], so modern toothpastes often contain between 30% and 40% abrasives, which are usually various shapes and sizes of silica particles. Other aspects to be considered are the varying lengths and designs of the studies as well as the different indices used to measure results, which could well influence outcomes. This was especially obvious in the plaque and gingivitis studies; in the studies on stain and calculus, the small number of articles also potentially affected clinical significance.

To conclude that the favorable results that the present review found are exclusively related to SnF~2~ content, identical toothpastes with and without SnF~2~ must be compared. Other factors, such as the unique silica content of the SnF~2~ toothpaste, may contribute to the positive findings.

4.6. Bias {#sec4.6}
---------

Analysis of the included papers followed SBU recommendations for quality assessment. Many of the studies were sponsored by the manufacturers or had authors employed by a toothpaste manufacturer. Although the studies were carefully executed and presented evidence of good quality, the involvement or support of the manufacturers could be regarded as a factor in potential bias. Additional studies that are less dependent on commercial interests and performed by independent researchers are needed. Studies with similar designs including comparable test and control products are necessary for conclusive findings.

5. Conclusion {#sec5}
=============

The present review found that stabilized SnF~2~ toothpaste had a positive effect on the reduction of dental calculus build-up, dental plaque, gingivitis, stain and halitosis. A tendency towards a more pronounced effect than using toothpastes not containing SnF~2~ was found, though the results of the individual trials in the meta-analyses showed a substantial heterogeneity. However, a new generation of well conducted randomized trials are needed to further support these findings.
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[^1]: BL (baseline), I (intervention), C (control), NaF (Sodium fluoride), SnF2 (Stannous fluoride), TCN (Triclosan), SHMP (Sodium hexametaphosphate), V-MI (Volpe-Manhold index).

[^2]: AlF (aluminium fluoride) BL (baseline), I (intervention), C (control), H (Hour) NaF (Sodium fluoride), SnF2 (Stannous fluoride), SnCl (stannous chloride), STP (sodium tripolyphosphate), SHMP (Sodium hexametaphosphate), SMFP (Sodium monofluorophosphate), PHEN (Phenolic essential oils), TCN (Triclosan), TP (Toothpaste), NS (not significant), vs (versus) Zn- citrate (Zink citrate).

[^3]: BL (baseline), I (intervention), C (control), NaF (Sodium fluoride), SnF2 (Stannous fluoride), TCN (Triclosan), TP (Toothpaste), H (Hours).

[^4]: BL (baseline), I (intervention), C (control), NaF (Sodium fluoride), SnF2 (Stannous fluoride), SnCl (stannous chloride), STP (sodium tripolyphosphate), SHMP (Sodium hexametaphosphate), MFP (monofluorphosphate) TCN (Triclosan), TP (Toothpaste), NS (not significant), vs (versus).
